Suzhou BioInno Bioscience Co., LtdN39.D54MPR BIO is a globally integrated CDMO partner and end-to-end execution platform established through a strategic joint venture between MPR Development Group and Suzhou BioInno Bioscience. Our mission is to advance exosome science and biopharmaceutical innovation by providing a unified pathway from initial development through to regional commercialization.
By addressing industry fragmentation with a single operational and governance framework, MPR BIO combines world-class exosome technologies and proprietary powdered insulin innovations with a comprehensive global infrastructure for development, regulatory strategy, manufacturing, and market access. Our platform is anchored by high-capacity CDMO facilities in Suzhou, advanced CMC and injectable formulation centers in Boston, and dedicated regional execution hubs across the Middle East, North Africa (MENA), Türkiye, and Central & Eastern Europe (CEE).
We deliver a robust portfolio that balances high-performance cosmetic applications – such as hair and facial treatments – with a clinically driven pathway for advanced therapeutic programs targeting pulmonary, nasal, bone, joint, and ophthalmic delivery. At MPR BIO, we are committed to a "registration-first" philosophy, ensuring that every product meets the highest standards of GMP manufacturing, batch consistency, and regulatory authorization before entering professional markets.
Core Capabilities & Reach:
Integrated CDMO Services: Full-service support including formulation, fill-finish, and commercial scale-up.
Scientific Leadership: Governed by a multidisciplinary committee of board-certified specialists to ensure clinical rigor and patient safety.
Regional Localization: Strategic focus on high-growth markets, including planned regional fill-finish capabilities in the Riyadh Free Trade Zone to accelerate market entry and institutional acceptance.
Unified Execution: A single-contract model that eliminates regional silos and allows programs to be allocated to the most suitable internal capabilities worldwide.
